“The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene Transcripts in Human Keratinocytes As Effectively As Dupilumab, and Blocks Th2 Inflammation in Atopic Dermatitis and Asthma Mouse Models”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s629. https://doi.org/10.25251/xbb5zx93.